摘要
目的:研究乳腺癌组织中抑癌基因PTEN编码蛋白的表达与肿瘤细胞增殖、侵袭转移的关系,探讨PTEN蛋白的表达在乳腺癌发生发展过程中的作用机制。方法:选取福州市第一医院病理科存档的乳腺癌标本86份和乳腺良性病变组织标本30份,应用免疫组织化学法检测乳腺癌组织和乳腺良性病变组织中PTEN表达情况与Ki67增殖指数,分析PTEN表达与乳腺癌Ki67增殖指数以及患者年龄、肿瘤大小、组织病理学分级、淋巴结转移、临床分期等临床病理学参数之间的关系。结果:乳腺癌组PTEN的阳性表达率为52.3%,良性对照组为93.3%;乳腺癌组Ki67增殖指数为(31.5±20.6)%,对照组为(9.7±6.9)%,比较均具有显著差异(P<0.01)。乳腺癌PTEN表达与Ki67增殖指数、组织病理学分级、腋窝淋巴结转移及临床分期呈负相关(P<0.05或P<0.01),与患者年龄、肿瘤大小未见显著相关(P>0.05)。结论:PTEN蛋白的表达与乳腺癌细胞增殖及侵袭转移具有相关性,是判断肿瘤生物学行为和患者预后的重要参考指标之一。
Objective： To investigate the expression of tumor suppressor gene PTEN-encoded protein in breast cancer tissues and its correlation with tumor cell proliferation, invasion and metastasis, so as to assess the role of PTEN protein in the carcinogenesis and progression of breast cancer. Methods： The expression of PTEN was examined by immunohistochemically in 86 breast cancer specimens （ keeped in Department of Pathology, First Hospital of Fuzhou） and 30 benign breast specimens;the proliferation index of Ki67 was obtained. The relationship between PTEN expression and Ki67 proliferation index, patient age, tumor size, histopathologic grade, axillary lymph-node metastasis, and clinical stage of breast cancer was analyzed. Results： The positive rate of PTEN was 52.3% in breast cancer group and 93.3% in the control group （P〈0.01） ; the Ki67 proliferation index was （31.5 ±20.6）% in breast cancer group and （9.7 ±6.9）% in the control group （P 〈0. 01 ）. PTEN expression was negatively related to Ki67 proliferation index, histopathological grade, axillary lymph-node metastasis and clinical stage of breast cancer （ P 〈 0. 05 or P 〈 0.01 ）, and was not related to patients age and tumor size （P 〉 0.05 ）. Conclusion： PTEN expression was related to the prohferation, invasion and metastasis of breast cancer cells and it can serve as an important marker for predicting biological behavior and prognosis of tumors.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2007年第4期373-376,共4页
Chinese Journal of Cancer Biotherapy
基金
福州市科技局科研基金资助项目(No2004350102000721)~~
作者简介
黄玉钿（1977-），男，福建省福州市人，硕士，医师，主要从事肿瘤病理的研究。
Correspondingauthor．E—mail：hydfz0591@163．com
